DeLLphi-304 — Tarlatamab vs Chemotherapy in Second-Line Small-Cell Lung Cancer

Phase 3 · 2025 · Small Cell Lung Cancer

Design

Multinational, open-label phase 3 randomizing to tarlatamab vs investigator's choice chemotherapy (topotecan, lurbinectedin, or amrubicin).

Population

Small-cell lung cancer that progressed during or after first-line platinum-based chemotherapy.

Primary Endpoint

overall survival (OS)

Key Result

Median OS 13.6 vs 8.3 mo with chemotherapy (HR 0.60); PFS and cancer-related dyspnea and cough also improved.

Guideline Impact

Second-line small-cell lung cancer